Last update 21 Nov 2024
Canlitinib
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC33H31F2N3O7 |
InChIKeyPCKYITPVOLEZKL-UHFFFAOYSA-N |
CAS Registry2222730-78-9 |
Related
12
Clinical Trials associated with CanlitinibA Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
评估KC1036对比研究者选择的化疗治疗晚期复发或转移性食管鳞癌受试者的随机、对照、开放、多中心III期临床研究
[Translation] A randomized, controlled, open-label, multicenter phase III clinical study evaluating KC1036 versus investigator-selected chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma
100 Clinical Results associated with Canlitinib
Login to view more data
100 Translational Medicine associated with Canlitinib
Login to view more data
100 Patents (Medical) associated with Canlitinib
Login to view more data
100 Deals associated with Canlitinib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | CN | 26 Jan 2024 | |
| Ewing Sarcoma | Phase 2 | CN | 05 Aug 2024 | |
| Metastatic thymic carcinoma | Phase 2 | CN | 07 Feb 2023 | |
| Recurrent Thymic Carcinoma | Phase 2 | CN | 07 Feb 2023 | |
| Metastatic Solid Tumor | Phase 2 | CN | 17 May 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 28 Aug 2020 | |
| Advanced Lung Adenocarcinoma | IND Approval | CN | 11 Jan 2023 | |
| Hematologic Neoplasms | Discovery | CN | 20 Nov 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05260385 (ASCO2023) Manual  | Phase 2 | 58 | (gyfbrhvxbg) = cgnkbygfmc jhubaizjes (hlozggchdp, 12.6 - 51.1) View more | Positive | 31 May 2023 | ||
Phase 1 | 41 | (lkquruwicm) = 60 mg QD opzaslfeja (bxvwiruvlr ) | Positive | 26 May 2023 | |||
Phase 1 | - | (vshmabwkfr) = Diarrhea (10.8%) dofojhievf (axhsorxcbq ) | Positive | 09 Jun 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free